BR112012026480A2 - combinações contendo 2,3-di-hidroimidazo[1,2-c]quinazolina substituída - Google Patents

combinações contendo 2,3-di-hidroimidazo[1,2-c]quinazolina substituída

Info

Publication number
BR112012026480A2
BR112012026480A2 BR112012026480A BR112012026480A BR112012026480A2 BR 112012026480 A2 BR112012026480 A2 BR 112012026480A2 BR 112012026480 A BR112012026480 A BR 112012026480A BR 112012026480 A BR112012026480 A BR 112012026480A BR 112012026480 A2 BR112012026480 A2 BR 112012026480A2
Authority
BR
Brazil
Prior art keywords
dihydroimidazo
quinazoline
combinations
component
containing substituted
Prior art date
Application number
BR112012026480A
Other languages
English (en)
Portuguese (pt)
Inventor
Ningshu Liu
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44144895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012026480(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of BR112012026480A2 publication Critical patent/BR112012026480A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112012026480A 2010-04-16 2011-04-14 combinações contendo 2,3-di-hidroimidazo[1,2-c]quinazolina substituída BR112012026480A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10160109 2010-04-16
PCT/EP2011/055917 WO2011128407A2 (en) 2010-04-16 2011-04-14 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Publications (1)

Publication Number Publication Date
BR112012026480A2 true BR112012026480A2 (pt) 2016-08-16

Family

ID=44144895

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012026480A BR112012026480A2 (pt) 2010-04-16 2011-04-14 combinações contendo 2,3-di-hidroimidazo[1,2-c]quinazolina substituída

Country Status (24)

Country Link
US (1) US20130184270A1 (https=)
EP (1) EP2558126A2 (https=)
JP (1) JP5886271B2 (https=)
KR (1) KR20130098155A (https=)
CN (1) CN102958540B (https=)
AU (1) AU2011240003A1 (https=)
BR (1) BR112012026480A2 (https=)
CA (1) CA2796253A1 (https=)
CL (1) CL2012002887A1 (https=)
CO (1) CO6620036A2 (https=)
CR (1) CR20120524A (https=)
CU (1) CU20120150A7 (https=)
DO (1) DOP2012000269A (https=)
EA (1) EA201201414A8 (https=)
EC (1) ECSP12012261A (https=)
IL (1) IL222356A0 (https=)
MA (1) MA34158B1 (https=)
MX (1) MX2012012064A (https=)
PE (1) PE20130191A1 (https=)
PH (1) PH12012502069A1 (https=)
SG (1) SG184550A1 (https=)
TN (1) TN2012000493A1 (https=)
WO (1) WO2011128407A2 (https=)
ZA (1) ZA201208616B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
WO2014160034A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Aldehyde dehydrogenase-1 modulators and methods of use thereof
CU24400B1 (es) 2013-04-08 2019-04-04 Bayer Pharma AG Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
WO2016142312A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
US10844066B2 (en) 2016-03-08 2020-11-24 Bayer Pharma Aktiengesellschaft 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
WO2019002068A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ATE411996T1 (de) * 2002-09-30 2008-11-15 Bayer Healthcare Ag Kondensierte azolpyrimidinderivate
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
DE102004064002B4 (de) 2004-08-04 2019-05-09 Continental Automotive Gmbh System zum Überwachen einer Sensorvorrichtung
CA2618218C (en) * 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
MX2010011314A (es) * 2008-04-14 2010-11-12 Ardea Biosciences Inc Composiciones y metodos de preparacion y uso de las mismas.
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Also Published As

Publication number Publication date
TN2012000493A1 (en) 2014-04-01
PH12012502069A1 (en) 2013-02-04
ZA201208616B (en) 2015-08-26
AU2011240003A1 (en) 2012-11-08
JP2013525293A (ja) 2013-06-20
WO2011128407A9 (en) 2011-12-22
EA201201414A1 (ru) 2013-04-30
CL2012002887A1 (es) 2013-01-18
EP2558126A2 (en) 2013-02-20
MA34158B1 (fr) 2013-04-03
CR20120524A (es) 2013-01-09
DOP2012000269A (es) 2012-12-15
KR20130098155A (ko) 2013-09-04
HK1182937A1 (en) 2013-12-13
US20130184270A1 (en) 2013-07-18
CA2796253A1 (en) 2011-10-20
CN102958540B (zh) 2015-09-02
WO2011128407A2 (en) 2011-10-20
MX2012012064A (es) 2012-12-17
EA201201414A8 (ru) 2013-12-30
IL222356A0 (en) 2012-12-31
PE20130191A1 (es) 2013-02-21
CU20120150A7 (es) 2013-02-26
JP5886271B2 (ja) 2016-03-16
ECSP12012261A (es) 2012-11-30
CN102958540A (zh) 2013-03-06
WO2011128407A3 (en) 2012-02-23
CO6620036A2 (es) 2013-02-15
SG184550A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
BR112012026480A2 (pt) combinações contendo 2,3-di-hidroimidazo[1,2-c]quinazolina substituída
MX2013003695A (es) Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida.
BR112017019188A2 (pt) Combinações contendo 2,3-di-hidroimidazo[1,2-c] quinazolina substituídas
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
ECSP088902A (es) Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios
BR112014029016A8 (pt) derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
AR062392A1 (es) Uso de compuestos y derivados de 2,5 dihidroxibenceno para el tratamiento de rosacea
NO20091254L (no) Terapeutiske sammensetninger
BR112014001369A2 (pt) derivados de ácido hidroxâmico de heteroarila e uso dos mesmos no tratamento, melhora ou prevenção de doença viral
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
BR112022004099A2 (pt) Composto, composição farmacêutica, uso do composto, e, método para o tratamento de uma doença relacionada ao atx
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
BR112014004732A2 (pt) composto benzotiazolona
BR112014004339A2 (pt) suspensão oral
CL2013003556A1 (es) Compuestos derivados de ftalazinona-pirrolo[3,2-d]pirimidin-carboxamida, inhibidoers de fosfodiesterasa tipo 4 y tipo 5; composcin farmaceutica que o comprende, combinacion fija, no fija y kit, uso del compuesto en la preparacion de un medicamento para trata enfermedaes de las vias respiratorias
BR112016009214A8 (pt) uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica
BR112013025410A2 (pt) tratamento terapêutico
TN2013000141A1 (en) Substituted n-(2-arylamino) aryl sulfonamide-containing combinations
BR112014001751A2 (pt) derivados de pirazolina e seu uso como moduladores seletivos do receptor de estrogênio
BR112012028376B8 (pt) Derivado inusitado da síntese de ecdisterona, seu método de preparação e uso
TH136433A (th) สูตรผสมและเกลือลิพอฟิลิคของเมทิลแนลเทร็กโซนที่ให้ทางปาก

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]